Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone Valerate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 13/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | MMP1 | P03956 | 10/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | MLNR | O43193 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.75 |
| ▸ | PPARG | P37231 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | DRD2 | P14416 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone Valerate SCHEMBL29407278 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL9768484 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL9768470 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL221479 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL16243364 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL11051241 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL14339607 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL7564753 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL14339612 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Dexamethasone Valarate SCHEMBL124723 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349981-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING BEXAROTENE AND A CORTICOSTEROID | ALMIRALL, S.A. (ES) | 2014-11-27 | — | — | US | disclosed |
| US-5026693-A | Novel 9α-fluoro- or chloro-corticosteroid esters and a process for their preparation | HOVIONE INTER LTD. (CH) | 1991-06-25 | — | — | US | disclosed |
| EP-0170500-A2 | Novel 9 alpha-fluoro- or chloro-corticosteroid esters and a process for their preparation | HOVIONE INTER LTD. (CH) | 1986-02-05 | — | — | EP | disclosed |
| US-4472393-A | ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION (US) | 1984-09-18 | — | — | US | disclosed |
| US-4427591-A | TOPICAL ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1984-01-24 | — | — | US | disclosed |
| US-4343739-A | OF 11-BETA-TRIHALOACYL-16-METHYLCORTICOSTEROID, SODIUM METHOXIDE CATALYST | PLURICHEMIE ANSTALT (LI) | 1982-08-10 | — | — | US | disclosed |
| US-4336200-A | 17α-Acyloxy-5β-corticoids | THE UPJOHN COMPANY (US) | 1982-06-22 | — | — | US | disclosed |
| US-4318853-A | ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1982-03-09 | — | — | US | disclosed |
| US-4267173-A | SAID HALOGENOCORTICOIDS BEING A 6B-FLUORO-7A-HALOGENO-1,4-PREGNADIENE | SCHERING CORPORATION (US) | 1981-05-12 | — | — | US | disclosed |
| US-4201778-A | 6-Acyloxy-1,4,6-pregnatrienes, their use as anti-inflammatory agents, methods for their manufacture, and 6-oxo-1,4-pregnadiene intermediates | SCHERING CORPORATION (US) | 1980-05-06 | — | — | US | disclosed |
| EP-0001864-A1 | Novel 6-oxygenated-3,20-dioxo-pregnane derivatives, process for the preparation thereof, and pharmaceutical compositions containing them | Technobiotic Ltd. (CH) | 1979-05-16 | — | — | EP | disclosed |
| US-4124707-A | 7α-Halogeno-3,20-dioxo-1,4-pregnadienes, methods for their manufacture, their use as anti-inflammatory agents, and pharmaceutical formulations useful therefor | SCHERING CORPORATION (US) | 1978-11-07 | — | — | US | disclosed |
| US-4083974-A | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether | THE UPJOHN COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
| US-3984544-A | Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor | SCHERING CORPORATION (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349981-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING BEXAROTENE AND A CORTICOSTEROID | SERPINA6, TSLP, CCL11 | NR3C1 47/4885PGR 285/4885CYP3A4 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.